ADC Therapeutics (ADCT) Assets Average (2021 - 2026)
ADC Therapeutics (ADCT) posted Assets Average of $307.3 million for Q1 2026, little changed sequentially from $306.5 million in Q4 2025, and up 3.39% YoY from $297.3 million in Q1 2025.
ADC Therapeutics (ADCT) Assets Average (2021 - 2026) Analysis & Trends
ADC Therapeutics has reported Assets Average for 6 years, with the latest figure at $307.3 million in Q1 2026.
- Quarterly Assets Average rose 3.39% year-over-year to $307.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $307.3 million (up 3.39% YoY) and the FY2025 annual result came in at $322.6 million, down 4.67% from the prior year.
- Assets Average was little changed at $307.3 million in Q1 2026 per ADCT's latest filing, from $306.5 million in the prior quarter.
- Over five years, Assets Average peaked at $599.9 million in Q1 2022 and troughed at $297.0 million in Q2 2025.
- A 5-year average of $407.9 million and a median of $360.4 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2024: Assets Average advanced 23.01% in 2022, then sank 30.86% in 2024.
- Over 5 years, Assets Average stood at $511.3 million in 2022, then retreated by 19.65% to $410.8 million in 2023, then declined by 18.33% to $335.5 million in 2024, then slipped by 8.67% to $306.5 million in 2025, then grew by 0.28% to $307.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $307.3 million, $306.5 million, and $305.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | ADC Therapeutics | 150.37 Mn | -68.74 Mn | 17.14 Mn | 285.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 285.44 Mn |
| Mar 31, 2026 | 307.32 Mn |
| Dec 31, 2025 | 306.45 Mn |
| Sep 30, 2025 | 305.66 Mn |
| Jun 30, 2025 | 297.05 Mn |
| Mar 31, 2025 | 297.26 Mn |
| Dec 31, 2024 | 335.53 Mn |
| Sep 30, 2024 | 360.43 Mn |
| Jun 30, 2024 | 339.87 Mn |
| Mar 31, 2024 | 331.37 Mn |
| Dec 31, 2023 | 410.84 Mn |
| Sep 30, 2023 | 487.10 Mn |
| Jun 30, 2023 | 487.49 Mn |
| Mar 31, 2023 | 479.27 Mn |
| Dec 31, 2022 | 511.31 Mn |
| Sep 30, 2022 | 526.11 Mn |
| Jun 30, 2022 | 551.17 Mn |
| Mar 31, 2022 | 599.93 Mn |
| Dec 31, 2021 | 627.98 Mn |
| Sep 30, 2021 | 551.18 Mn |